WO2004050903A3 - Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine - Google Patents

Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine Download PDF

Info

Publication number
WO2004050903A3
WO2004050903A3 PCT/EP2003/013199 EP0313199W WO2004050903A3 WO 2004050903 A3 WO2004050903 A3 WO 2004050903A3 EP 0313199 W EP0313199 W EP 0313199W WO 2004050903 A3 WO2004050903 A3 WO 2004050903A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
pde4c
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2003/013199
Other languages
English (en)
Other versions
WO2004050903A2 (fr
Inventor
Klaus Muenter
Erwin Bischoff
Peter Ellinghaus
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Klaus Muenter
Erwin Bischoff
Peter Ellinghaus
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Klaus Muenter, Erwin Bischoff, Peter Ellinghaus, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003288158A priority Critical patent/AU2003288158A1/en
Publication of WO2004050903A2 publication Critical patent/WO2004050903A2/fr
Publication of WO2004050903A3 publication Critical patent/WO2004050903A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a trait à une PDE4C humaine qui est associée aux troubles des systèmes nerveux périphérique et central, à des maladies cardiovasculaires (en particulier l'angine de poitrine et la cardiopathie coronaire), à des maladies hématologiques, à des inflammations, au cancer, à des maladies gastro-entérologiques et à des maladies respiratoires. L'invention concerne également des dosages permettant d'identifier les composés utiles pour le traitement ou la prévention de troubles des systèmes nerveux périphérique et central, de maladies cardiovasculaires (en particulier l'angine de poitrine et la cardiopathie coronaire), de maladies hématologiques, d'inflammations, du cancer, de maladies gastro-entérologiques et de maladies respiratoires. L'invention se rapporte aussi à des composés qui se lient à PDE4C et/ou activent ou inhibent son activité, ainsi qu'à des compositions pharmaceutiques contenant de tels composés.
PCT/EP2003/013199 2002-12-04 2003-11-25 Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine WO2004050903A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003288158A AU2003288158A1 (en) 2002-12-04 2003-11-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026971A EP1426767A1 (fr) 2002-12-04 2002-12-04 Diagnostic et traitement pour des maladies associées au phosphodiesterase 4c humain (PDE4C)
EP02026971.8 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050903A2 WO2004050903A2 (fr) 2004-06-17
WO2004050903A3 true WO2004050903A3 (fr) 2004-08-19

Family

ID=32309368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013199 WO2004050903A2 (fr) 2002-12-04 2003-11-25 Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine

Country Status (3)

Country Link
EP (1) EP1426767A1 (fr)
AU (1) AU2003288158A1 (fr)
WO (1) WO2004050903A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010517A2 (fr) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap)
EP2430191B1 (fr) 2009-05-12 2018-09-19 Koninklijke Philips N.V. Phosphodiestérase 4D7 en tant que marqueur du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025138A2 (fr) * 1998-10-23 2000-05-04 Roger Nitsch Methodes de diagnostic ou de pronostic de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025138A2 (fr) * 1998-10-23 2000-05-04 Roger Nitsch Methodes de diagnostic ou de pronostic de la maladie d'alzheimer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOLGER G ET AL: "A FAMILY OF HUMAN PHOSPHODIESTERASES HOMOLOGOUS TO THE DUNCE LEARNING AND MEMORY GENE PRODUCT OF DROSOPHILA MELANOGASTER ARE POTENTIAL TARGETS FOR ANTIDEPRESSANT DRUGS", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 13, no. 10, 1 October 1993 (1993-10-01), pages 6558 - 6571, XP000566626, ISSN: 0270-7306 *
MIRO X ET AL: "cAMP-specific phosphodiesterases PDE4, PDE4D splice variants and PDE7A: differential regulation of their mRNAs following acute systemic inflammatory response in rat brain", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 724.6, XP001188954, ISSN: 0190-5295 *
PEREZ-TORRES S ET AL: "Cellular expression of cAMP phosphodiesterase PDE4A, PDE4B and PDE4D mRNAs in Alzheimer's disease brains", ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 1, 2001, pages 1134, XP002271232, ISSN: 0190-5295 *
PEREZ-TORRES S ET AL: "Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and (3H)rolipram binding autoradiography comparison with monkey and rat brain", JOURNAL OF CHEMICAL NEUROANATOMY, vol. 20, no. 3-4, December 2000 (2000-12-01), pages 349 - 374, XP002275597, ISSN: 0891-0618 *
PERSANI L ET AL: "RELEVANT CAMP-SPECIFIC PHOSPHODIESTERASE ISOFORMS IN HUMAN PITUITARY: EFFECT OF GSALPHA MUTATIONS", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 86, no. 8, August 2001 (2001-08-01), pages 3795 - 3800, XP001151837, ISSN: 0021-972X *

Also Published As

Publication number Publication date
WO2004050903A2 (fr) 2004-06-17
EP1426767A1 (fr) 2004-06-09
AU2003288158A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004050903A3 (fr) Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2004042390A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4b (pde4b) humaine
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004104574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2004029617A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase humaine 11a (pde11a)
WO2004071394A3 (fr) Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2003100435A3 (fr) Procede pour diagnostiquer et traiter des maladies associees au recepteur de neuromedine u2 (nmu2)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2004042077A3 (fr) Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004042388A3 (fr) Diagnostics et medicaments pour des maladies associees a la phosphodiesterase 8a (pde8a) humaine
WO2003100434A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 2 de l'arginine vasopressine (avpr2)
WO2004042387A3 (fr) Diagnostics et traitements de maladies associees a la phosphodiesterase 11a1 humaine (pde11a1)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2005101009A3 (fr) Outils diagnostiques et therapeutiques pour maladies associees au recepteur 2 de tachykinine (tacr2)
WO2004097422A3 (fr) Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP